| 1 | Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans' affairs medical center. (Benz S, Sherman KA, Dasanu CA, Alvarez-Argote J) J Oncol Pharm Pract 2024 Jun;30(4):697-704 3 Citations |
| 1 | Clinical concept and relation extraction using prompt-based machine reading comprehension. (Peng C, Yang X, Yu Z, Bian J, Hogan WR, Wu Y) J Am Med Inform Assoc 2023 Aug 18;30(9):1486-1493 20 Citations |
| 1 | Potential Impact of Pharmacogenomic Single Nucleotide Variants in a Rural Caucasian Population. (Williams GR, Tsongalis GJ, Lewis LD, Barney RE, Cook LJ, Aaron Geno K, Nerenz RD) J Appl Lab Med 2023 Mar 06;8(2):251-263 |
| 1 | Models of determinants of COVID-19 vaccine hesitancy in non-pregnant and pregnant population: Review of current literature". (Tostrud L, Thelen J, Palatnik A) Hum Vaccin Immunother 2022 Nov 30;18(6):2138047 31 Citations |
| 2 | Common Presentations of Rare Drug Reactions and Atypical Presentations of Common Drug Reactions in the Intensive Care Unit. (Tanem JM, Scott JP) Crit Care Clin 2022 Apr;38(2):287-299 |
| 1 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H) Lancet Oncol 2021 Sep;22(9):1290-1300 340 Citations |
| 1 | Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. (Narla S, Silverberg JI, Simpson EL) J Am Acad Dermatol 2022 Mar;86(3):628-636 72 Citations |
| 1 | Moving Beyond 3+3: The Future of Clinical Trial Design. (Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RC MD, Hong DS) Am Soc Clin Oncol Educ Book 2021 Jun;41:e133-e144 |
| 1 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. (Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C) Lancet Oncol 2021 Jun;22(6):790-800 348 Citations |
| 2 | Aromatase Inhibitor Symptom Management Practices: A Retrospective Study. (Ernst A, Flynn KE, Weil EM, Crotty BH, Kamaraju S, Fergestrom N, Neuner J) Clin Breast Cancer 2021 Feb;21(1):e38-e47 6 Citations |
| 1 | Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. (Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA) Clin Cancer Res 2020 Nov 01;26(21):5579-5587 25 Citations |
| 1 | Esketamine: A Novel Option for Treatment-Resistant Depression. (Bozymski KM, Crouse EL, Titus-Lay EN, Ott CA, Nofziger JL, Kirkwood CK) Ann Pharmacother 2020 Jun;54(6):567-576 67 Citations |
| 1 | Identifying relations of medications with adverse drug events using recurrent convolutional neural networks and gradient boosting. (Yang X, Bian J, Fang R, Bjarnadottir RI, Hogan WR, Wu Y) J Am Med Inform Assoc 2020 Jan 01;27(1):65-72 52 Citations |
| 1 | Phase I trials as valid therapeutic options for patients with cancer. (Adashek JJ, LoRusso PM, Hong DS, Kurzrock R) Nat Rev Clin Oncol 2019 Dec;16(12):773-778 100 Citations |
| 1 | Medications and Vocal Function. (Bock JM) Otolaryngol Clin North Am 2019 Aug;52(4):693-702 9 Citations |
| 1 | Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. (Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR) Clin Cancer Res 2019 Jul 15;25(14):4264-4270 76 Citations |
| 1 | MADEx: A System for Detecting Medications, Adverse Drug Events, and Their Relations from Clinical Notes. (Yang X, Bian J, Gong Y, Hogan WR, Wu Y) Drug Saf 2019 Jan;42(1):123-133 48 Citations |
| 2 | Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. (Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J) Oncologist 2019 Jul;24(7):955-962 33 Citations |
| 1 | Serum retinyl esters are positively correlated with analyzed total liver vitamin A reserves collected from US adults at time of death. (Olsen K, Suri DJ, Davis C, Sheftel J, Nishimoto K, Yamaoka Y, Toya Y, Welham NV, Tanumihardjo SA) Am J Clin Nutr 2018 Nov 01;108(5):997-1005 28 Citations |
| 1 | Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. (Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB) Transfusion 2017 Nov;57(11):2775-2781 28 Citations |
| 1 | Clinical Practice Guideline: Safe Medication Use in the ICU. (Kane-Gill SL, Dasta JF, Buckley MS, Devabhakthuni S, Liu M, Cohen H, George EL, Pohlman AS, Agarwal S, Henneman EA, Bejian SM, Berenholtz SM, Pepin JL, Scanlon MC, Smith BS) Crit Care Med 2017 Sep;45(9):e877-e915 79 Citations |
| 2 | Seasonal Variation in Pediatric Chronic Pain Clinic Phone Triage Call Volume. (Jastrowski Mano KE, Gibler RC, Rusy LM, Ladwig RJ, Madormo CO, Hainsworth KR) Pain Manag Nurs 2017 Oct;18(5):288-294 2 Citations |
| 1 | Incidence of Adverse Contrast Reaction Following Nonintravenous Urinary Tract Imaging. (Blackwell RH, Kirshenbaum EJ, Zapf MAC, Kothari AN, Kuo PC, Flanigan RC, Gupta GN) Eur Urol Focus 2017 Feb;3(1):89-93 15 Citations |
| 1 | Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. (Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA) Clin Cancer Res 2017 Aug 01;23(15):4027-4034 42 Citations |
| 1 | Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. (Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, Patel N) Ann Pharmacother 2017 May;51(5):365-372 18 Citations |
| 1 | Medication Harmony: A Framework to Save Time, Improve Accuracy and Increase Patient Activation. (Pandolfe F, Crotty BH, Safran C) AMIA Annu Symp Proc 2016;2016:1959-1966 7 Citations |
| 2 | The Missing Record of Mental Status in Written Sign-Outs. (Croix M, Miller D, Whittle J, Singh S, Schapira MM, Carnahan J, Kuester J, Kallio C, Framberg S, Fletcher KE) J Patient Saf 2019 Dec;15(4):e40-e43 |
| 2 | Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project. (Pratt VM, Everts RE, Aggarwal P, Beyer BN, Broeckel U, Epstein-Baak R, Hujsak P, Kornreich R, Liao J, Lorier R, Scott SA, Smith CH, Toji LH, Turner A, Kalman LV) J Mol Diagn 2016 Jan;18(1):109-23 122 Citations |
| 1 | Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. (Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA) Clin Gastroenterol Hepatol 2015 Dec;13(13):2233-40.e1-2; quiz e177-8 97 Citations |
| 1 | Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children? (Hayashi M, Strouse JJ, Veltri MA, Curtis BR, Takemoto CM) Pediatr Blood Cancer 2015 May;62(5):922-3 4 Citations |
| 1 | Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. (Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV) Annu Rev Pharmacol Toxicol 2015;55:89-106 401 Citations |
| 1 | Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms. (Curtis BR) Immunohematology 2014;30(2):55-65 71 Citations |
| 1 | Drug-induced immune neutropenia/agranulocytosis. (Curtis BR) Immunohematology 2014;30(2):95-101 88 Citations |
| 1 | Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. (Liu S, Kurzrock R) Cancer Treat Rev 2014 Aug;40(7):883-91 143 Citations |
| 1 | Adverse Drug Event-based Stratification of Tumor Mutations: A Case Study of Breast Cancer Patients Receiving Aromatase Inhibitors. (Wang C, Zimmermann MT, Prodduturi N, Chute CG, Jiang G) AMIA Annu Symp Proc 2014;2014:1160-9 2 Citations |
| 1 | Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. (McGivern JV, Ebert AD) Adv Drug Deliv Rev 2014 Apr;69-70:170-8 24 Citations |
| 1 | Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. (Mokhtarani M, Diaz GA, Rhead W, Berry SA, Lichter-Konecki U, Feigenbaum A, Schulze A, Longo N, Bartley J, Berquist W, Gallagher R, Smith W, McCandless SE, Harding C, Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS Jr, Dickinson K, Moors T, Norris C, Coakley D, Milikien DA, Nagamani SC, Lemons C, Lee B, Scharschmidt BF) Mol Genet Metab 2013 Dec;110(4):446-53 35 Citations |
| 1 | Drug-induced thrombocytopenia in children. (Reese JA, Nguyen LP, Buchanan GR, Curtis BR, Terrell DR, Vesely SK, George JN) Pediatr Blood Cancer 2013 Dec;60(12):1975-81 25 Citations |
| 1 | Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. (Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS) Clin Cancer Res 2013 Sep 01;19(17):4824-31 22 Citations |
| 1 | Safety of midazolam for sedation of HIV-positive patients undergoing colonoscopy. (Backman ES, Triant VA, Ehrenfeld JM, Lu Z, Arpino P, Losina E, Gandhi RT) HIV Med 2013 Jul;14(6):379-84 2 Citations |
| 1 | Using multiple cause-of-death data to improve surveillance of drug-related mortality. (Nordstrom DL, Yokoi-Shelton ML, Zosel A) J Public Health Manag Pract 2013;19(5):402-11 12 Citations |
| 1 | Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. (Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R) Clin Cancer Res 2012 Oct 15;18(20):5796-805 79 Citations |
| 1 | Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes. (Paul LJ, Cohen PR, Kurzrock R) Int J Dermatol 2012 Jun;51(6):631-46; quiz 643-4, 646 18 Citations |
| 1 | Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants. (Ehrenpreis ED, Sifuentes H, Ehrenpreis JE, Smith ZL, Marshall ML) Expert Opin Drug Saf 2012 Mar;11(2):177-83 7 Citations |
| 1 | Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. (Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K) J Am Acad Dermatol 2012 May;66(5):742-51 131 Citations |
| 1 | Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. (Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH) J Am Acad Dermatol 2012 Feb;66(2):241-51 161 Citations |
| 1 | Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. (Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J, ABT-874 Study Investigators) J Am Acad Dermatol 2011 Feb;64(2):263-74 27 Citations |
| 1 | A preliminary report of parent/nurse-controlled analgesia (PNCA) in infants and preschoolers. (Czarnecki ML, Salamon KS, Jastrowski Mano KE, Ferrise AS, Sharp M, Weisman SJ) Clin J Pain 2011 Feb;27(2):102-7 |
| 1 | Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. (Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM) J Am Acad Dermatol 2010 Sep;63(3):448-56 146 Citations |
| 1 | Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK) Blood 2010 Sep 23;116(12):2127-33 127 Citations |
| 1 | Towards an ontological theory of substance intolerance and hypersensitivity. (Hogan WR) J Biomed Inform 2011 Feb;44(1):26-34 5 Citations |
| 1 | Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. (Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS) J Clin Oncol 2009 Jul 20;27(21):3557-65 228 Citations |
| 2 | High-dose selenium for the mitigation of radiation injury: a pilot study in a rat model. (Sieber F, Muir SA, Cohen EP, North PE, Fish BL, Irving AA, Mäder M, Moulder JE) Radiat Res 2009 Mar;171(3):368-73 44 Citations |
| 1 | Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings. (Murphy BA, Chen A, Curran WJ Jr, Garden AS, Harari PM, Wong SJ, Ang KK) Support Care Cancer 2009 Nov;17(11):1393-401 11 Citations |
| 1 | Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. (Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P) Leuk Lymphoma 2008 Nov;49(11):2141-7 59 Citations |
| 1 | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). (Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators) Lancet 2008 May 17;371(9625):1675-84 1389 Citations |
| 1 | Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. (Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E) J Child Adolesc Psychopharmacol 2006 Oct;16(5):575-87 129 Citations |
| 1 | Finding the maximum safe dose level for heteroscedastic data. (Tamhane AC, Logan BR) J Biopharm Stat 2004 Nov;14(4):843-56 18 Citations |
| 1 | Drug usage in the elderly. (Lund MD, Duthie EH Jr) Wis Med J 1982 Aug;81(8):21-5 2 Citations |
